Academic Jobs Logo

Rate My Professor Fedja Rochling

University of Nebraska Medical Center

Manage Profile
5.00/5 · 1 review
5 Star1
4 Star0
3 Star0
2 Star0
1 Star0
5.05/4/2026

Helps students see the bigger picture.

About Fedja

Fedja Rochling, MBBCh, MBA, serves as Professor and Chief of the Division of Gastroenterology and Hepatology in the Department of Internal Medicine at the University of Nebraska Medical Center. A graduate of the Royal College of Surgeons in Dublin, Ireland (MBBCh, 1989), he also holds an MBA from the University of Nebraska College of Business (2014). His training encompasses house officership at Newcastle General Hospital and Freeman Hospital, UK (1990); internal medicine residency at Baylor College of Medicine, Houston (1993); hepatology fellowship at University of Texas Southwestern Medical Center, Dallas (1995); and gastroenterology fellowship at Medical College of Wisconsin, Milwaukee (1998). Before joining UNMC faculty in 2002, he was on faculty at the University of Arkansas. He has served as interim division chief (2019-2020), acting chief (2018), and permanent chief since February 2024. Additionally, he is chief of gastroenterology at the Omaha VA Medical Center, associate program director for the gastroenterology fellowship, and co-director of the GI curriculum in UNMC's medical education program.

Board certified in internal medicine, gastroenterology, and transplant hepatology, Rochling focuses clinically on liver disease, liver cancer, and short bowel syndrome. His research interests include clinical studies on intestinal failure through collaboration with the Intestinal Rehabilitation Program, as well as liver cancer, short bowel syndrome, and medical education. Key publications include "Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis" (The Lancet Oncology, 2009; 2518 citations), "Acetaminophen toxicity in an urban county hospital" (New England Journal of Medicine, 1997; 610 citations), "Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis" (The Lancet Gastroenterology & Hepatology, 2017; 230 citations), and "Current management of short bowel syndrome" (Current Problems in Surgery, 2012; 156 citations). His work demonstrates significant impact in hepatology and gastroenterology, evidenced by high citation counts and contributions to patient care and training.